The effectiveness and safety of human urinary kallidinogenase in acute ischemic stroke patients undergoing endovascular therapy

Abstract

The effectiveness and safety of human urinary kallidinogenase (HUK) in acute ischemic stroke (AIS) patients undergoing endovascular therapy (EVT) due to large vessel occlusion (LVO) was unclear. A pooled analysis was performed using individual data from the DEVT and RESCUE BT trials. Patients were divided into two groups based on HUK treatment. The primary outcome was the 90-day modified Rankin Scale (mRS) score. Safety outcomes included 90-day mortality and symptomatic intracranial hemorrhage (sICH) within 48 hours. A total of 1174 patients were included in the study. Of these, 150 (12.8%) patients received HUK. The adjusted common odds ratio (OR) of the mRS score was 1.458 (95% confidence interval [CI] = 1.072–1.983; p = 0.016) favoring HUK. The incidence of sICH (2.0% vs. 8.6%; adjusted OR: 0.198; 95% CI: 0.061–0.638; p = 0.007) and mortality (11.3% vs.18.5%; adjusted OR: 0.496; 95% CI: 0.286–0.862; p = 0.013) was lower in HUK group than non-HUK group. This association was consistent with propensity score-matching and the inverse probability of treatment weighting analysis. In conclusion, HUK was safe and associated with a preferable prognosis in AIS patients due to LVO in the anterior circulation.

Keywords

Human urinary kallidinogenase endovascular therapy large vessel occlusion stroke

Get full access to this article

View all access options for this article.

References

Feigin

Stark

Johnson

, et al. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet Neurol 2021; 20: 795–820.

Mosconi

Paciaroni

Treatments in ischemic stroke: Current and future. Eur Neurol 2022; 85: 349–366.

Kang

D-H

Jung

Yoon

, et al. Endovascular thrombectomy for acute basilar artery occlusion: a multicenter retrospective observational study. J Am Heart Assoc 2018; 7: e009419.

Albert-Weißenberger

Sirén

A-L

Kleinschnitz

Ischemic stroke and traumatic brain injury: the role of the kallikrein-kinin system. Prog Neurobiol 2013; 101–102: 65–82.

Chao

Shen

Gao

, et al. Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem 2010; 391: 345–355.

Miao

Deng

Zhang

, et al. Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke. Neurosciences (Riyadh) 2016; 21: 126–130.

Zhang

Ding

Yan

, et al. Plasma tissue kallikrein level is negatively associated with incident and recurrent stroke: a multicenter Case-Control study in China. Ann Neurol 2011; 70: 265–273.

Ling

Yang

, et al. High level of serum tissue kallikrein is associated with favorable outcome in acute ischemic stroke patients. Dis Markers 2019; 2019: 5289715.

Zhang

Tao

Liu

, et al. Efficacy and safety of human urinary kallidinogenase injection for acute ischemic stroke: a systematic review. J Evid Based Med 2012; 5: 31–39.

10.

Qiu

, DEVT Trial Investigatorset al. Effect of endovascular treatment alone vs intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke: the DEVT randomized clinical trial. JAMA 2021; 325: 234–243.

11.

Qiu

Sang

, et al. Effect of intravenous tirofiban vs placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke the RESCUE BT randomized clinical trial. JAMA 2022; 328: 543–553.

12.

Kwah

Diong

National institutes of health stroke scale (NIHSS). J Physiother 2014; 60: 61–61.

13.

Adams

Jr. Bendixen

Kappelle

, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke 1993; 24: 35–41.

14.

Coutts

Demchuk

Barber

, VISION Study Groupet al. Interobserver variation of ASPECTS in real time. Stroke 2004; 35: E103–E105.

15.

Higashida

Furlan

Roberts

, et al. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003; 34: E109–E137.

16.

Silva

Elawady

Maier

, et al. 2C or not 2C: defining an improved revascularization grading scale and the need for standardization of angiography outcomes in stroke trials. J Neurointerv Surg 2014; 6: 83–86.

17.

Banks

Marotta

CA.

Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007; 38: 1091–1096.

18.

Agha

Abdall-Razak

Crossley

, et al. STROCSS 2019 guideline: strengthening the reporting of cohort studies in surgery. Int J Surg 2019; 72: 156–165.

19.

Xia

Yin

Borlongan

, et al. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 2004; 43: 452–459.

20.

Liu

Zhang

Liu

, et al. Tissue kallikrein protects cortical neurons against in vitro ischemia-acidosis/reperfusion-induced injury through the ERK1/2 pathway. Exp Neurol 2009; 219: 453–465.

21.

Liu

Zhang

Liu

, et al. Tissue kallikrein alleviates glutamate-induced neurotoxicity by activating ERK1. J Neurosci Res 2009; 87: 3576–3590.

22.

van Horn

Kniep

Leischner

, et al. Predictors of poor clinical outcome despite complete reperfusion in acute ischemic stroke patients. J Neurointerv Surg 2021; 13: 14–18.

23.

Yang

Jin

Song

, et al. Futile recanalization after endovascular treatment in patients with acute basilar artery occlusion. Neurosurgery 2022; 92: 1006–1012.

24.

Nogueira

Jadhav

Haussen

, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018; 378: 11–21.

25.

Goyal

Menon

van Zwam

, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016; 387: 1723–1731.

26.

Nagano

Suzuki

Hayashi

, et al. Effects of a human urinary kininogenase (SK-827) on cerebral microcirculation after glass bead-induced cerebral embolism in rabbits. In Vivo 1992; 6: 497–502.

27.

Yao

Wang

, et al. Human urinary kallidinogenase in acute ischemic stroke: a single-arm, multicenter, phase IV study (RESK study). CNS Neurosci Ther 2021; 27: 1493–1503.

28.

Wang

Chen

Zhang

, et al. Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction. Eur Rev Med Pharmacol Sci 2015; 19: 1009–1012.

29.

Jing

Analysis of treatment effect of urinary kallidinogenase combined with edaravone on massive cerebral infarction. Biomed Rep 2016; 5: 155–158.

30.

Lin

Y-H

Liu

H-M.

Update on cerebral hyperperfusion syndrome. J Neurointerv Surg 2020; 12: 788–793.

31.

Chen

Z-b

Huang

D-q

Niu

F-n

, et al. Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappa B. J Cereb Blood Flow Metab 2010; 30: 1356–1365.

32.

Ibrahim

Goverman

Sarhane

, et al. The emerging role of tissue plasminogen activator in the management of severe frostbite. J Burn Care Res 2015; 36: E62–E66.

33.

Mocco

Mack

Ducruet

, et al. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res 2006; 99: 209–217.

34.

Nagano

Suzuki

Tomoguri

, et al. Pharmacological studies on human urinary kallidinogenase (SK-827): effects on cerebral metabolism. Yakugaku Zasshi 1993; 113: 825–828.

35.

Venema

SMU

Dankbaar

van der Lugt

, et al. Cerebral collateral circulation in the era of reperfusion therapies for acute ischemic stroke. Stroke 2022; 53: 3222–3234.

36.

Desai

Jha

Linfante

Collateral circulation augmentation and neuroprotection as adjuvant to mechanical thrombectomy in acute ischemic stroke. Neurology 2021; 97: S178–s184.

37.

Savitz

Baron

J-C

Fisher

Stroke treatment academic industry roundtable X brain cytoprotection therapies in the reperfusion era. Stroke 2019; 50: 1026–1031.

38.

Han

Chen

, et al. Human urinary kallidinogenase promotes angiogenesis and cerebral perfusion in experimental stroke. PLoS One 2015; 10: e0134543.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.43 MB